Associations of Accelerometer-Determined Sedentary and Physical Activity Behaviors with Heart Failure Biomarkers during Midlife: CARDIA Study

中年时期基于加速度计测定的久坐和身体活动行为与心力衰竭生物标志物的关联:CARDIA 研究

阅读:1

Abstract

BACKGROUND: Few studies have examined the longitudinal associations of accelerometer-based measures of sedentary and physical activity behaviors with subclinical heart failure (HF) in midlife. This is a key gap, given that an improved understanding of modifiable factors associated with HF risk may better inform prevention strategies. We hypothesize that more time in light intensity physical activity and/or moderate or vigorous intensity physical activity (MVPA) and less sedentary time will be related to lower levels of HF biomarkers (N-terminal pro B-type natriuretic peptide and high-sensitivity cardiac troponin T [hscTnT]) across midlife. METHODS: Data are from 2494 Coronary Artery Risk Development in Young Adults (CARDIA) participants without clinical HF (58.9% women, 45.7% Black persons, mean [±standard deviation] aged 51.1 ± 7.2 yr at the baseline contributing exam) with at least one occurrence of concurrent valid accelerometer (ActiGraph 7164/GT3X; Ametris; Pensacola, FL) wear and HF biomarkers at the CARDIA year 20, 30 and/or year 35 follow-up examinations. Adjusted linear mixed effects models were used to estimate the associations. Heterogeneity in the associations by the four race-sex groups represented in CARDIA was also examined. RESULTS: In the fully adjusted models, every 5-min higher MVPA was associated with -0.05 (95% confidence interval: -0.09 to -0.01, P = 0.022) lower hscTnT. The associations of sedentary and light intensity physical activity with hscTnT and associations of any accelerometer estimate with N-terminal pro B-type natriuretic peptide were not statistically supported (all P > 0.05). Findings were similar when clinically relevant categories of HF biomarker outcomes were used in the analysis. CONCLUSIONS: Findings address research gaps in the literature and demonstrate the importance of MVPA during the midlife transition for HF prevention before the onset of overt signs or symptoms.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。